Nirmatrelvir/Ritonavir (Paxlovid®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2026. COVID-19 FAQs for obstetrician-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed June 2026
- Anderson PO. 2022. COVID-19 drugs and breastfeeding update. Breastfeed Med; 17:377–9.
- Chourasia P, et al. 2023. Paxlovid (nirmatrelvir and ritonavir) use in pregnant and lactating woman: Current evidence and practice guidelines-a scoping review. Vaccines (Basel); 11:107.
- Chuang MT, et al. 2024. Transplacental passage of nirmatrelvir in pregnant women with COVID-19. Int J Gynaecol Obstet; 164(1):351-353.
- Corbett AH, al. 2014. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: Results of the BAN Study. Antivir Ther; 19:587–595.
- Dai J, et al. 2024. Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk. Clin Pharmacol Ther; 116(5):1217-1221.
- Gandhi M, et al. 2013. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr; 63:578-584.
- Garneau WM, et al. 2022. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for acute SARS-CoV-2 infection. JAMA Netw Open; 5(11):e2244141.
- Lin CY, et al. 2023. Nirmatrelvir-ritonavir (Paxlovid) for mild coronavirus disease 2019 (COVID-19) in pregnancy and lactation. Obstet Gynecol; 141:957–60.
- Lin CW, et al. 2023. Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic. J Infect Public Health; 16(12):1942-1946.
- Loza A, et al. 2022. Short-term pregnancy outcomes after nirmatrelvir-ritonavir treatment for mild-to-moderate coronavirus disease 2019 (COVID-19). Obstet Gynecol; 140(3):447-449.
- Palombi L, et al. 2012. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther; 17:1511–1519.
- Pfizer Laboratories Div Pfizer Inc. Last updated October 18, 2023. Paxlovid drug label. Source: National Library of Medicine. Available

at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a. Accessed June 2026.

- Ramírez-Ramírez A, et al. 2018. Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method. PLoS One; 13:e0191236.
- Rezk NL, et al. 2008. Studies on antiretroviral drug concentrations in breast milk: Validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit; 30:611–9.
- Yang H, et al. 2025. Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy. Matern Child Health J; 29(5):599-603.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Nirmatrelvir/Ritonavir (Paxlovid®)

Selected References:

- Campbell LS, et al. 2025. Balancing Mental Health and Breastfeeding: Evaluating the Transfer of Lurasidone Into Human Milk. J Clin Psychiatry; 86(4):25m15955.
- Cohen LS, et al. 2023. Reproductive safety of lurasidone and quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J Womens Health (Larchmt); 32(4):452-462.
- Cruz MP. 2011. Lurasidone HCl (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of

patients with schizophrenia. P & T: a peer-reviewed journal for formulary management; 36(8):489–492.

- Damkier, P & Videbech, P. 2018. The safety of second-generation antipsychotics during pregnancy: A clinically focused review. CNS Drugs; 32:351–366.
- FDA. 2011. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Previously retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.
- Greenberg WM & Citrome L. 2017. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet; 56:493–503.
- Kantrowitz JT, Citrome L. 2012. Lurasidone for schizophrenia: what's different? Expert Rev Neurother; 12(3):265-73.
- Keightley P, et al. 2020. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry; 54:1035–1036.
- Kernizan N, et al. 2024. Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes. Bipolar Disord; 26(8):779-784.
- Kernizan N, et al. 2025. Prescribing Patterns for the Treatment of Bipolar Disorder in Pregnancy: A Retrospective Cohort Study. J Clin Med; 14(5):1638.
- Luo Z, et al. 2025. The safety analysis of lurasidone based on the real-world data of FAERS database. Expert Opin Drug Saf; 1-11.
- Montiel C, et al. 2022. Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol; 30(2):249-252.
- Sumitomo Pharma America, Inc. (Last updated 2025). Latuda drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8.
- Terrana N, et al. 2015. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology; 35(5):559–565.
- Viguera AC, et al. 2022. Breastfeeding practices among women taking second-generation antipsychotics: Findings from the National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health; 25:511–6.
- Wang E, et al. 2025. Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes. CNS Drugs; 39(1):1-22.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Nirmatrelvir/Ritonavir (Paxlovid®)

Selected References:

- Barr M Jr, Cohen MM Jr. 1991. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology; 44:485-495.
- Bhatt-Mehta V, Deluga KS. 1993. Fetal exposure to lisinopril: neonatal manifestations and management. Pharmacotherapy;13(5): 515-518.
- Burrows RF, Burrows EA. 1998. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol; 38(3):306-311.
- Chugh J, Dai J, Datta P, Krutsch K. 2025. Investigating the transfer of lisinopril into human milk: a quantitative analysis. J CardiovascPharmacol;85(1):4-87.
- Cooper WO, et al. 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med; 354(23): 2443-2451.
- Diav-Citrin O, et al. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol; 31(4):540-545.
- Filler G, et al. 2003. Early dialysis in a neonate with intrauterine lisinopril exposure. Arch Dis Child Fetal Neonatal Ed,88(2):F154-156.
- Friedman JM. 2006. ACE inhibitors and congenital anomalies. NEnglJ Med, 354:2498-2500.
- Karthikeyan VJ, et al. 2011. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens, 29(2):396-399.
- Lennestal R, et al. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol, 65(6):615-625.
- Lip GYH, et al. 1997. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet, 350:1446-1447.
- Merck Sharp and Dohme Corp. 2018. Prinivil product label. Moretti ME, et al. 2012. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int; 2012:658310.
- Moretti ME, et al. 2012. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int; 2012:658310.
- National Collaborating Centre for Women’s and Children’s Health (UK). 2011. Hypertension in Pregnancy. Appendix O. Safety of commonly used antihypertensive drugs during breastfeeding. NICE ClinicalGuidelines, No. 107. London: RCOG Press.
- Polifka JE.2012.Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth Defects Res (Part A), 94:576-598.
- Pryde PG, et al. 1993. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol,3:1575-1582.
- Rosa F, Bosco L. 1991. Infant renal failure with maternal ACE inhibition. Am JObstetGynecol, 161(1 Part 2):273

(abstract).

- Tomlinson AJ, et al. 2000. Malignant primary hypertension in pregnancy treated with lisinopril. Ann Pharmacother,34(2):180-182.
- U.S. Food and Drug Administration (FDA).1992.Upgraded warning on the use of ACE inhibitors during pregnancy.
- Yip SK, et al.1998. Exposure to angiotensin-converting enzyme inhibitors duringfirsttrimester: is it safe to fetus? Acta Obstet Gynecol Scand; 77:570-571.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Nirmatrelvir/Ritonavir (Paxlovid®)

Selected References:

- Atmaca M, Kuloglu M, Tezcan E, Canatan H, Gecici,O. 2002. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 33:562-5.
- Beumont PJ, Gelder MG, Friesen HG, et al. 1974. The effects of phenothiazine on endrocrine function: I Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry. 124:413–9.
- Crawford AM, Beasley CM Jr, Tollefson GD. 1997. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 26:41–54.
- Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. J Affect Disord. 373:495-504.
- Diav-Citrin O, Shechtman S, Ornoy S, et al. 2005. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Journal of Clinical Psychiatry 66:317-322.
- Dieulangard P et al. 1966. Sur un cas d’ectro-phocomelie peutetre d’origine medicamenteuse. Bull Fed Gynecol Obstet 18:85-87.
- Fiore L, Scapagnini U, Canonico PL. 1987. Effect of dihydroergocryptine and dihydroergocristine on cyclic AMP

accumulation and prolactin release in vitro: Evidence for a dopaminomimetic action. Horm Res. 25:171–177.

- Kallen et al. 2013 The use of central nervous system active drugs during pregnancy. Pharmaceuticals 6(10):1221-1286.
- Kopelman AE et al. 1975. Limb malformations following maternal use of haloperidol. J Am Med Assoc 231:62-64.
- Langer G, Puhringer W. 1980. Haloperidol and droperidol treatment in schizophrenics. Clinical application of the «prolactin-model». Acta Psychiatr Belg. 80:574–83.
- Maguire GA. 2002. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 63(suppl 4):56-62.
- Straub L, Hernández-Díaz S, Bateman BT, et al. 2022. Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study. JAMA Intern Med. 182(5):522–533.
- Straub L, et al. 2026. Congenital malformation risk following prenatal antipsychotic exposure: a systematic safety surveillance approach. BMJ Ment Health. 29(1):e302270.
- Turkington RW. 1972. Prolactin secretion in patients treated with various drugs: Phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med. 130:349–354.
- Turkington RW. 1972. Serum prolactin levels in patients with gynecomastia. J Clin Endocrinol Metab. 34:62–66.
- Uguz F. 2016. Breastfed infants exposed to combined antipsychotics: Two case reports. Am J Ther. 23:e1962–e1964
- Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. Breastfeed Med. 14:683–684.
- Uguz F. 2021. A new safety scoring system for the use of psychotropic drugs during lactation. Am J Ther. 28:e118–e126
- Van Waes A, Van de Velde E. 1969. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 9:224-227.
- Wang, E., et al.. 2026. Correction: Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. CNS Drugs 40, 841–863.
- Whalley LJ, Blain PG, Prime JK. 1981. Haloperidol secreted in breast milk. Br Med J (Clin Res Ed). 282:1746–1747.
- Yoshida K, Smith B, Craggs M, et al. 1997. Investigation of pharmacokinetics and possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord. 43:225–237.
- Yoshida K, Smith B, Craggs M, et al. 1998. Neuroleptic drugs in breast-milk: A study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med. 28:81–91.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Nirmatrelvir/Ritonavir (Paxlovid®)

Selected References:

- Appiah-Sakyi K, et al. 2020. Ebola infection in pregnancy, an ongoing challenge for both the global health expert and the pregnant woman-A review. Eur J Obstet Gynecol Reprod Biol. 258:111-117.
- Baggi FM, et al. 2014 Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill. 19(49):20983.
- Baraka NK, et al. 2019. One month follow up of a neonate born to a mother who survived Ebola virus disease during pregnancy: a case report in the Democratic Republic of Congo. BMC Pediatr, 19(1):202.
- Bebell LM, et al. 2017. Ebola virus disease and pregnancy: A review of the current knowledge of Ebola virus pathogenesis, maternal, and neonatal outcomes. Birth Defects Res. 109(5):353-362.
- Beigi RH. 2017. Emerging infectious diseases in pregnancy. Obstet Gynecol. 129(5):896-906.
- Centers for Disease Control and Prevention (CDC). 2023. Guidance for Personal Protective Equipment (PPE). https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/guidance/index.html. Accessed May 20, 2026.
- Centers for Disease Control and Prevention. 2024. Clinical Guidance for Ebola in Pregnant Women. https://www.cdc.gov/ebola/hcp/clinical-guidance/clinical-guidance-for-ebola-in-pregnant-women.html. Accessed May 20, 2026.
- Centers for Disease Control and Prevention. 2025. Clinical Guidance for Neonates Born to Patients with Suspected or Confirmed Ebola Disease. https://www.cdc.gov/ebola/hcp/clinical-guidance/clinical-guidance-for-neonates-born-to-patients-with-suspected-or-confirmed-ebola-disease.html. Accessed June 10, 2026.
- Centers for Disease Control and Prevention. 2025. Ebola Disease and Breastfeeding. Ebola Disease and Breastfeeding | Breastfeeding special circumstances | CDC. Accessed June 10, 2026.
- Centers for Disease Control and Prevention. 2025. Ebola Vaccine Product Information. https://www.cdc.gov/ebola/hcp/vaccines/index.html. Accessed May 21, 2026.
- Centers for Disease Control and Prevention. 2026. Ebola Disease Basics. https://www.cdc.gov/ebola/about/index.html. Accessed May 19, 2026.
- Chughtai AA, et al. 2016. Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiol Infect. 144(8):1652-60.
- Deen GF, et al. 2017. Ebola RNA persistence in semen of Ebola virus disease survivors – Final Report. N Engl J Med. 377(15):1428-1437.
- Foeller ME, et al. 2020. Pregnancy and breastfeeding in the context of Ebola: a systematic review. Lancet Infect Dis. 20(7):e149-e158.
- Henwood PC, et al. 2017 Ebola Virus Disease and pregnancy: A retrospective cohort study of patients managed at 5 Ebola treatment units in West Africa. Clin Infect Dis. 65(2):292-299.
- Kayem ND, et al. 2022. Ebola virus disease in pregnancy: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 116(6):509-522.
- Keita AK, et al; PostEbogui Study Group. 2019. A 40-month follow-up of Ebola virus disease survivors in Guinea (PostEbogui) reveals long-term detection of Ebola viral ribonucleic acid in semen and breast milk. Open Forum Infect Dis. 6(12):ofz482.
- Medina-Rivera M, et al. 2021. Presence of Ebola virus in breast milk and risk of mother-to-child transmission: synthesis of evidence. Ann N Y Acad Sci. 1488(1):33-43.
- Mupapa K, et al. 1999. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 179 Suppl 1:S11-2.
- Pimundu G, et al. 2026. Investigating the Sudan virus outbreak in Uganda through the deployment of a mobile

laboratory. BMC Infect Dis. 16;26(1):175.

- Sayres L, Hughes BL. 2020. Contemporary understanding of Ebola and Zika Virus in pregnancy. Clin Perinatol. 47(4):835-846.
- Schieffelin JS, et al. 2014. KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 371(22):2092-100.
- Sissoko D, et al. 2017. Ebola virus persistence in breast milk after no reported illness: A likely source of virus transmission from mother to child. Clinical Infectious Diseases. 64(4):513–516.
- Waitt C, et al. 2025. Scarcity of research on breastfeeding and Ebola diseases is placing the lives of women and infants at risk: a call to specific action. Lancet Glob Health. 13(2):e364-e371.
- World Health Organization. 2020. Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease. WHO guidelines approved by the Guidelines Review Committee. https://iris.who.int/server/api/core/bitstreams/96592e3e-26b8-4a10-aa30-d5dc87d71192/content. Accessed June 5, 2026.
- World Health Organization. 2016. Interim advice on the sexual transmission of the Ebola virus disease. https://cdn.who.int/media/docs/default-source/documents/publications/interim-advice-on-the-sexual-transmission-of-the-ebola-virus-disease68aa1c7c-301c-41bf-a165-9ca3e3ac4ab7.pdf. Accessed June 9, 2026.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.